JG-98
CAS No. 1456551-16-8
JG-98 ( JG98 )
产品货号. M11970 CAS No. 1456551-16-8
JG-98 是一种变构 Hsp70 抑制剂,对乳腺癌细胞系 MDA-MB-231 和 MCF-7 的活性和稳定性比 MKT-077 高 3 倍以上(EC50 分别为 0.4 uM 和 0.7 uM)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥1473 | 有现货 |
|
| 5MG | ¥2404 | 有现货 |
|
| 10MG | ¥2993 | 有现货 |
|
| 25MG | ¥4920 | 有现货 |
|
| 50MG | ¥6770 | 有现货 |
|
| 100MG | ¥8847 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称JG-98
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述JG-98 是一种变构 Hsp70 抑制剂,对乳腺癌细胞系 MDA-MB-231 和 MCF-7 的活性和稳定性比 MKT-077 高 3 倍以上(EC50 分别为 0.4 uM 和 0.7 uM)。
-
产品描述JG-98 is an allosteric Hsp70 inhibitor, displays >3-fold more active, greater stability than MKT-077 against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 of 0.4 uM and 0.7 uM, respectively); strongly affects autophagic flux, increases p62 oligomerization and reduces p62 monomer; destabilizes FoxM1 and relieved suppression of downstream effectors, including p21 and p27.
-
体外实验JG-98 (30 nM-30 μM; 72 hours) has antiproliferative activity across a range of cell lines with the EC50s between ~0.3 and 4 μM.JG-98 (10 μM; 48 hours) activates apoptotic mediators (cleavage of caspase-3 and PARP) in MDA-MB-231 cells.JG-98 destabilizes FoxM1 and relieves suppression of downstream effectors, including p21 and p27. Cell Proliferation Assay Cell Line:MCF-7, MDA-MB-231, A375, MeWo, HeLa, HT-29, SKOV3, Jurkat, mouse embryonic fibroblasts (MEF), MM1.R, INA6, RPMI-8226, JJN-3, U266, NCI-H929, L363, MM1.S, KMS11, LP-1, AMO-1, OPM1, OPM2 cells Concentration:30 nM-30 μM Incubation Time:72 hours Result:Active against all of the lines tested, and the EC50s were variable (between ~0.3 μM and 4 μM). Normal MEFs and OPM1 and OPM2 were relatively less sensitive.Western Blot Analysis Cell Line:MDA-MB-231 cells Concentration:10 μM Incubation Time:48 hours Result:Incudes apoptotic mediators cleavage of caspase 3 and PARP.
-
体内实验JG-98 (3 mg/kg; i.p.; on days 0, 2, and 4) suppresses tumor growth in xenograft models bearing MCF7 and HeLa cells. Animal Model:6-week-old NCR mice (xenografts of MCF7 and HeLa cells) Dosage:3 mg/kg Administration:Intraperitoneal injection; on days 0, 2, and 4 Result:Limited tumor growth, but somewhat less effectively.
-
同义词JG98
-
通路Cytoskeleton/Cell Adhesion Molecules
-
靶点HSP
-
受体HSP70
-
研究领域——
-
适应症——
化学信息
-
CAS Number1456551-16-8
-
分子量534.532
-
分子式C24H21Cl2N3OS3
-
纯度>98% (HPLC)
-
溶解度DMSO: Soluble ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESCCN1C(=CC2=[N+](C=CS2)CC3=CC=CC=C3)SC(=C4N(C5=C(S4)C=C(C=C5)Cl)C)C1=O.[Cl-]
-
化学全称Thiazolium,2-[(Z)-[(5E)-5-(6-chloro-3-methyl-2(3H)-benzothiazolylidene)-3-ethyl-4-oxo-2-thiazolidinylidene]methyl]-3-(phenylmethyl)-,chloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Li X. et al. ACS Med Chem Lett. 2013 Nov 14;4(11).
2. Li X, et al. Mol Cancer Ther. 2015 Mar;14(3):642-8.
产品手册
关联产品
-
PU-H71 HCl
PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of malignancy. PU-H71 HCL has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.
-
AMP-PCP
AMP-PCP 是 ATP 类似物,可以结合 Hsp90 N 末端结构域,Kd 值为 3.8 μM。 AMP-PCP 结合有利于 Hsp90 活性同二聚体的形成。
-
KNK-437
一种热休克蛋白 (HSP) 合成抑制剂,可剂量依赖性地抑制人结肠癌细胞耐热性的获得和各种 HSP(包括 HSP105、HSP70 和 HSP40)的诱导。
021-51111890
购物车()
sales@molnova.cn

